K2 PRINCIPAL FUND L.P. 13D/13G Filings for TCR2 Therapeutics Inc. (TCRR)

K2 PRINCIPAL FUND L.P. 13D and 13G filings for TCR2 Therapeutics Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2023-02-08
5:51 pm
Sale		 2022-12-31 13G TCR2 Therapeutics Inc.
TCRR		 K2 PRINCIPAL FUND L.P. 0
0.000%		 -1,950,628decrease
(Position Closed)		 Filing
2022-08-31
6:13 pm
Purchase		 2022-08-26 13G TCR2 Therapeutics Inc.
TCRR		 K2 PRINCIPAL FUND L.P. 1,950,628
5.050%		 1,950,628increase
(New Position)		 Filing